Receptor de células T E7 (TCR): terapia de inducción de células T para cánceres asociados con el VPH avanzados locorregionalmente
Un estudio de viabilidad de la terapia de inducción de células TCR-T E7 para cánceres asociados al VPH avanzados locorregionalmente
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival.
This study seeks to determine 1) if E7 TCR-T cells can be administered without undue delay in definitive treatment, 2) the tumor response rate to E7 TCR-T cell treatment, and 3) the disease-free survival rate at 2 and 5 years.
Participants will undergo an apheresis procedure to obtain T cells that will be genetically engineered to generate E7 TCR-T cells. They will receive a conditioning regimen, a single infusion of their own E7 TCR-T cells, and adjuvant aldesleukin. Participants will follow up to assess safety and determine tumor response and will return to their primary oncology team for definitive therapy.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
- Cáncer de cuello uterino
- Neoplasia maligna relacionada con el VPH
- Cáncer de vulva
- Cáncer de ano
- Cáncer de orofaringe
- Cáncer de vagina
- Carcinoma relacionado con el VPH
- Carcinoma de células escamosas de orofaringe positivo para VPH
- Cáncer de pene
- Carcinoma de cuello uterino asociado al VPH
- Adenocarcinoma relacionado con el VPH
- Carcinoma adenoescamoso relacionado con el VPH
- Carcinoma de células escamosas relacionado con el VPH
- Carcinoma anal de células escamosas relacionado con el VPH
- Carcinoma de células escamosas del pene relacionado con el VPH
- Carcinoma de células escamosas de la vulva relacionado con el VPH
- Adenocarcinoma endocervical relacionado con el VPH
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a single-arm, single-cohort, single-center, feasibility study to determine the feasibility of E7 TCR-T cell induction therapy for locoregionally advanced human papillomavirus (HPV)-associated cancers (LAHPVC). Participants must have LAHPVC with HPV-16-positive cancer (tumor test) and the human leukocyte antigens (HLA)-A*02:01 allele (blood test). Participants will undergo apheresis for generation of autologous, gene-engineered, E7 TCR-T cells. One week after apheresis, they will receive a non-myeloablative lymphocyte-depleting preparative regimen of cyclophosphamide and fludarabine. Conditioning will be followed by a single infusion of E7 TCR T cells and adjuvant high-dose aldesleukin. Participants will follow up 3 weeks and 6 weeks after treatment. Tumor response will be assessed by imaging studies at the 6-week time point. Participants will be referred back to their primary oncology team for definitive therapy after the 6-week assessment (or earlier if tumors do not appear to be responding). Participants will be followed to determine 2- and 5-year disease free survival.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Cell Therapy Clinical Research Team
- Número de teléfono: 732-235-7356
- Correo electrónico: celltherapy@cinj.rutgers.edu
Ubicaciones de estudio
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Reclutamiento
- Rutgers Cancer Institute
-
Contacto:
- Cell Therapy Clinical Research Team
- Número de teléfono: 732-235-7356
- Correo electrónico: celltherapy@cinj.rutgers.edu
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Reclutamiento
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
Contacto:
- Cell Therapy Clinical Research Team
- Número de teléfono: 732-235-7356
- Correo electrónico: celltherapy@cinj.rutgers.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria: Subjects must meet all the following criteria to participate in this study.
-
Histologically confirmed carcinoma of a primary tumor site and stage indicated in Table 3 of the protocol.
-
Tumor with HPV16 genotype as determined by testing performed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.
-
HLA-A*02:01 allele determined by testing performed in a CLIA certified laboratory. Participants may be enrolled based on low resolution typing (i.e., HLA-A*02) but the HLA-A*02:01 allele type must be confirmed prior to apheresis.
-
Measurable disease per RECIST Criteria Version 1.1 or PERCIST.
-
Age ≥ 18 years.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.
-
Negative pregnancy test for women under 55 and all women who have had a menstrual period in the last 12 months. A pregnancy test is not required for women who have had a bilateral oophorectomy or hysterectomy.
-
Men and women of child-bearing potential must agree to use adequate contraception (i.e., intrauterine device, hormonal barrier method of birth control, abstinence, tubal ligation, or vasectomy) prior to study entry and for four months after treatment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.
-
Seronegative for HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C antibody. If a hepatitis C antibody test is positive, then testing for antigen by reverse transcription polymerase chain reaction (RT-PCR) must be negative.
-
Participants must have organ and marrow function as defined below:
- Leukocytes > 3,000/mcL
- Absolute neutrophil count > 1,500/mcL
- Platelets > 100,000/mcL
- Hemoglobin > 9.0 g/dL
- Total bilirubin within normal institutional limits except in participants with Gilbert's Syndrome who must have a total bilirubin < 3.0 mg/dL.
- Serum aspartate aminotransferase (AST) (SGOT)/ alanine transaminase (ALT) (SGPT) < 2.5 x upper limit of normal (ULN)
- Calculated creatinine clearance (CrCl) >50 mL/min/1.73 m2 for participants with creatinine levels above institutional normal (by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation).
- International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤1.5 X ULN unless the subject is receiving anticoagulant therapy. Subjects on anticoagulant therapy must have a PT or aPTT within therapeutic range and no history of severe hemorrhage.
-
Participants must be able to understand and be willing to sign the written informed consent document.
-
Participants must agree to participate in Rutgers protocol 192103 (Pro2021002307) for gene therapy long term follow up and in Rutgers protocol 192002 (Pro2021000281) for biospecimen studies.
Note: Patients may have undergone minor surgical procedures with the past three weeks, as long as all toxicities have recovered to Grade 1 or less.
Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in this study:
-
Have received prior systemic therapy or definitive chemoradiation for the cancer that is being treated on this protocol. Palliative radiation therapy for symptom management, such as to control tumor-induced bleeding, is permitted.
-
Current treatment with another investigational agent.
-
History of severe allergic reactions to compounds of similar chemical or biological composition to agents used in this study.
-
Uncontrolled intercurrent illness such as active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations at the time of treatment that would limit compliance with study requirements.
-
Subjects with HLA-A*02:01 damaging mutation or allele loss detected by research or clinical sequencing will not be eligible.
-
Documented LVEF of less than or equal to 45% tested. The following participants will undergo cardiac evaluations:
- Clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or
- Age ≥ 50 years old
-
Participants with baseline screening pulse oxygen level of ≤ 92% on room air will not be eligible. If the underlying cause of hypoxia improves, they may be reevaluated.
-
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with E7 TCR T cells, breastfeeding should be discontinued if the mother is treated with E7 TCR T cells. These potential risks may also apply to other agents used in this study.
-
Participants with a systemic immunodeficiency including acquired deficiency such as HIV or primary immunodeficiency such as Severe Combined Immunodeficiency Disease are ineligible. The experimental treatment being evaluated in this protocol depends on an intact immune system. Participants who have decreased immune competence may be less responsive to the treatment.
-
Participants on immunosuppressive drugs including corticosteroids unless meeting criteria outlined in Section 6.1 (Prohibited Medications).
-
Participants with potentially severe autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, autoimmune hepatitis, autoimmune pancreatitis, or systemic lupus erythematosus are not eligible. Patients with less severe autoimmune diseases such as hypothyroidism, vitiligo, and other minor autoimmune disorders are eligible.
-
Participants with prior or concurrent malignancy whose natural history or treatment is unlikely to interfere with the safety or efficacy assessments of the investigational regimen are eligible for this trial. Examples include, but are not limited to:
- Carcinoma in situ
- Cutaneous skin cancers requiring only local excision
- Low grade non-muscle invasive bladder cancer
- Low grade prostate cancer
-
Subjects who received a live vaccine within 30 days prior to enrollment are not eligible.
-
Determination by the Principal Investigator that participation is not in the best interest of the research subject or may jeopardize the safety of the subject or integrity of the clinical trial data.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: E7 TCR-T cells
Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. |
Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
Otros nombres:
Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV will be administered every 8 hours as an inpatient for up to 3 doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility of administering E7 TCR-T cell therapy as induction treatment for LAHPVC
Periodo de tiempo: 6 weeks
|
Proportion of subjects who complete treatment without an event that meets criteria for feasibility failure |
6 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective tumor response rate at 6-weeks after treatment
Periodo de tiempo: 6 weeks
|
Tumor response as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) criteria Version 1.1 or PERCIST |
6 weeks
|
|
2-year and 5-year disease free survival (DFS)
Periodo de tiempo: 5 years
|
DFS will be determined using the Kaplan-Meier method |
5 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Christian S Hinrichs, MD, Rutgers Cancer Institute
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades Estomatognáticas
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades urogenitales masculinas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades intestinales
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias colorrectales
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades uterinas
- Enfermedades Genitales Femeninas
- Neoplasias de Cabeza y Cuello
- Neoplasias Genitales Femeninas
- Enfermedades del cuello uterino
- Enfermedades Otorrinolaringológicas
- Neoplasias Uterinas
- Neoplasias faríngeas
- Neoplasias Otorrinolaringológicas
- Enfermedades faríngeas
- Enfermedades Vulvares
- Enfermedades del Ano
- Enfermedades del pene
- Enfermedades vaginales
- Neoplasias Rectales
- Neoplasias del cuello uterino
- Neoplasias Vulvares
- Neoplasias orofaríngeas
- Neoplasias del Ano
- Neoplasias Penianas
- Neoplasias vaginales
- Técnicas de investigación
- Terapéutica
- Terapia biológica
- Técnicas inmunológicas
- Inmunomodulación
- Inmunización, pasiva
- Inmunización
- Inmunoterapia
- aldesleucina
- Transferencia adoptiva
Otros números de identificación del estudio
Otros números de identificación del estudio
- 192104
- Pro2022000437 (Otro identificador: Rutgers, The State University of New Jersey)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Marco de tiempo para compartir IPD
Data will be made available through the publisher at the time of publication.
Criterios de acceso compartido de IPD
Data will be accessible through the publisher.
Tipo de información de apoyo para compartir IPD
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .